P-172 - IMPACT OF BIOLOGICAL EFFECTIVE DOSES IN HEPATIC SBRT
P-173 - IMPACT OF COVID-19 PANDEMIC IN OUR RADIOTHERAPY ONCOLOGY DEPARTMENT
P-174 - IMPACT OF DIFFERENCE DISTRIBUTION IN METASTATIC FREE SURVIVAL: HDR BRACHYTHERAPY.
P-175 - IMPACT OF PLANNING TARGET VOLUMEN IN OUTCOMES IN LUNG CANCER.
P-176 - IMPACT OF RADIATION TECHNIC IN ANAL CANCER
P-177 - IMPACT OF RADIATION-DOSE AND SURVIVAL IN LUNG CANCER PALLIATIVE RADIOTHERAPY
P-178 - IMPACT OF RADIOTHERAPY ON QUALITY OF LIFE
P-179 - IMPACT OF RADIOTHERAPY SCHEDULES ON BREAST CANCER PATIENTS’ QOL (EQ-5D-5L AND FACT-B+4)
P-180 - IMPLEMENTATION OF A TREATMENT START CHECKLIST IN A MOBILE APPLICATION
P-181 - IMPLEMENTATION OF CHECKLISTS FOR QUALITY CONTROL OF THE RADIOTHERAPY TREATMENTS
P-182 - IMPLEMENTING A QUALITY MANAGEMENT SYSTEM IN A RADIOTHERAPY DEPARTMENT
P-183 - IMPORTANCE OF ISO-9001:2015 CERTIFICATION IN A MULTIDISCIPLINARY INTRAOCULAR TUMOR UNIT
P-184 - IMPROVED QUALITY OF RADIOTHERAPY SIMULATION CT
P-185 - INFLUENCE OF RADIATION TREATMENT TECHNIQUE IN ANAL CANCER.
P-186 - INFLUENCE OF RADIATION TREATMENT TECHNIQUE IN OESOPHAGEAL CANCER
P-187 - INITIAL CLINICAL EXPERIENCE WITH PROTON REIRRADIATION: A OPTIMIZED THERAPEUTIC OPTION
P-188 - INITIAL DOSIMETRIC PARAMETERS ANALYSES BETWEEN PHOTONS & PROTONS.
P-189 - INITIAL EXPERIENCE WITH APALUTAMIDE IN METASTATIC HORMONO-SENSITIVE PROSTATE CANCER (MHSPC)
P-190 - INITIAL EXPERIENCE WITH DAROLUTAMIDE IN NON-METASTATIC PROSTATE CANCER (CPRCM0)
P-191 - INITIAL RESULTS OF APALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
P-192 - INOPERABLE EARLY BREAST CANCER TREATED WITH RADIOTHERAPY BY WEEKLY SCHEME